CRNX Crinetics Pharmaceuticals, Inc. Insider Trading

Chief Dev. & Operating Officer Knight sold 85,163 shares of CRNX at $40.10 (-44.7% of holdings); stock now down 30.1% from 52-week high.

Knight executed a substantial sale reducing his CRNX holdings by 44.7%, from 190,452 to 105,289 shares, at $40.10 per share for $3,415,036.30. His prior three sales at this ticker were all well-timed, with 90-day declines of -6.5%, -3.4%, and -2.6%, establishing a consistent pattern of selling ahead of price weakness. The stock has since fallen 30.1% from its 52-week high of $56.43 and currently trades at $39.44, materially below the transaction price. This follows a company profile showing severe unprofitability ($-130.1M net loss in latest full year) against a $4.1B market cap, despite 640.7% annual revenue growth from a minimal $143.0K quarterly revenue base. The magnitude of the sale and the insider's historical accuracy at timing exits at this ticker merit close monitoring given the company's financial distress and recent stock deterioration.

CEO Struthers sold 21,981 shares (22.0K) for $821,513.01 on 2026-03-16; stock down 36.1% from 52-week high, 4 of 5 prior CRNX sales were well-timed.

Richard Scott Struthers, President & CEO, executed 2 separate sales totaling 21,981 shares for $821,513.01, reducing his holdings by 5.2% to 404,778 shares. The sales occurred at $37.11 and $37.77 per share, with a blended average of $37.37, while the stock currently trades at $36.05—down 15.6% over 30 days and 36.1% from its 52-week high of $56.43. Notably, Struthers' prior 5 trades at CRNX show a pattern of well-timed sales, with 4 of the previous 5 sales followed by 90-day negative returns (ranging from -37.8% to -4.0%), suggesting an established track record of selling before declines. The company is unprofitable ($-130.1M net income) despite strong revenue growth of 640.7%, and the stock's recent weakness into this sale warrants investor attention to whether the CEO's selling behavior signals an assessment of near-term risks.

CSO Betz sells 97,483 shares (97.5K) of CRNX at $32.23; cuts stake by 49.4% to 99.7K shares remaining.

Betz Stephen F., Chief Scientific Officer, executed a substantial single-tranche sale of 97,483 shares at $32.23 on 2025-06-12, reducing his holdings from 197.2K to 99.7K shares—a 49.4% reduction that leaves him with nearly equal pre- and post-transaction stakes. The sale occurred at a price point $0.99 above the current market price of $31.20, though the stock remains down 48.6% from its 52-week high of $60.69. Crinetics remains deeply unprofitable with a net loss of $-96.8M in the most recent full fiscal year, annual revenue that has contracted 74.1%, and quarterly revenue of only $361.0K—a biotech company in a preclinical or early-stage position with substantial capital burn. The scale of this liquidation (nearly half his holdings) by an executive responsible for scientific strategy warrants examination of the company's scientific outlook, pipeline progress, and capital runway relative to burn rate.

CRNX CEO Struthers sells 17,338 shares for $593,016.96; stock down 43.3% from 52-week high, -35.8% in 90 days.

Richard Scott Struthers, President & CEO, executed 2 separate sales totaling 17,338 shares (17.3K shares) for $593,016.96 on 2025-03-19, reducing his holdings by 5.0% to 329,147 shares. The sales occurred at blended average price $34.20, against a current price of $34.42, in a stock that has declined 43.3% from its 52-week high and fallen 35.8% over the past 90 days. The company reported negative net income of $-76,828,000.00 and zero revenue in the latest quarter, alongside annual revenue growth of -74.1% year-over-year, signaling severe operational contraction. Prior sales at CRNX show mixed timing outcomes: 2 of 5 prior sells achieved well-timed 90-day results, but the most recent sale on 2024-12-02 was followed by a 90-day decline of -37.8%, indicating the insider has captured downside protection in at least one recent instance.

CEO Struthers sold 10,000 shares at $57.57; down 9.1% from 110.0K holdings. CRNX stock -15.3% YoY, unprofitable at -$76.8M net income.

Richard Scott Struthers, President & CEO, sold 10,000 shares (10.0K shares) on 2024-12-02 at $57.57, reducing his holdings to 100,000 shares (100.0K shares). The sale occurs as Crinetics faces deteriorating fundamentals: the company generated zero revenue in its latest quarter, posted a net loss of $-76,828,000.00 ($-76.8M) and experienced annual revenue decline of -15.3%. At the ticker level, his prior 5 sales at CRNX showed inconsistent timing, with only 1 of 5 well-timed at the 90-day mark, while his cross-ticker track record shows a 90d well-timed rate of 12.50%. The current sale occurs near the 52-week high range (down 5.9% from peak of $60.69), with stock up 12.0% over 90 days, creating a backdrop where an inside seller's risk assessment warrants investor attention given the company's cash burn trajectory and operating losses.

CFO Marc Wilson sold 25,000 CRNX shares at $51.11; holds 111,092 post-sale. Stock -7.1% from 52-week high; company posted -$74.1M net loss.

CFO Marc Wilson sold 25,000 shares (18.4% reduction in holdings) at $51.11 on 2024-09-26, leaving him with 111,092 shares. The sale occurred when CRNX was trading -7.1% from its 52-week high and near recent 52-week lows, suggesting the CFO was willing to exit at depressed valuations. Crinetics is unprofitable—the latest full fiscal year produced a net loss of -$74.1M against quarterly revenue of $399.0K—and revenue has contracted 15.3% year-over-year, signaling material operational stress. Among Wilson's three prior CRNX trades, his timing record has been poor: two recent 2024 sales (2024-07-25 and 2024-07-15) showed negative returns at 30-day follow-up (-1.4% and -6.5%), and an earlier 2024-06-28 sale that appeared positive at 30 days (+24.6%) has since turned to a 90-day return of +16.0%, meaning he sold before a subsequent rally—demonstrating 0 of 1 well-timed 90-day outcomes at this ticker. The combination of large position reduction, sales occurring near 52-week lows, and consistent under-performance of prior trade timing at CRNX warrants attention to whether the CFO holds different conviction than market technicals suggest.

CFO Wilson Marc sold 19,056 shares of CRNX at $53.88 on 2024-07-25, reducing holdings by 14.6% to 111,092 shares.

Wilson Marc, serving as CFO, sold 19,056 shares worth $1,026,737.28 at $53.88, the second of two consecutive sales within a 27-day window (prior sale on 2024-07-15, and another on 2024-06-28). The stock has risen sharply in recent months (30-day change: +28.8%, 90-day change: +29.1%) and is now trading only 1.1% below its 52-week high of $54.98, suggesting he sold into recent strength. However, the company faces fundamental headwinds: revenue declined 15.3% year-over-year to $640,000.00 in the latest quarter, net income was negative at $-66,930,000.00, and the company remains unprofitable on an annual basis. The pattern of three sales within roughly a month—without corresponding gains elsewhere—occurs against a backdrop of continued operational losses, though no prior trade timing data is yet measurable for the recent CRNX sales.

COO Knight sold 27,000 shares at $55.00 on 2024-07-15, reducing stake 34.3%; stock near 52-week peak, company unprofitable.

Chief Operating Officer Jeff E. Knight sold 27,000 shares at $55.00, representing 34.3% of his pre-transaction holdings and reducing his position from 78.7K to 51.7K shares. The sale occurred near the 52-week high ($54.98), with the stock up 20.4% over 30 days and 25.2% over 90 days. Knight's same-ticker history shows 2 prior sells at CRNX (both on 2024-03-22) that were well-timed at the 90-day mark, with the stock declining -0.0% and -2.6% thereafter. The underlying company context adds weight to this pattern: Crinetics reported only $640.0K quarterly revenue against a $-66.9M net loss, reflecting annual revenue decline of -15.3% year-over-year while operating at significant losses. The combination of a substantial equity stake reduction at elevated valuations, consistent historical success in sell-timing at this ticker, and deteriorating financial performance warrants investor scrutiny.

CFO Wilson Marc sold 25,000 shares of CRNX at $55.00 on 2024-07-15 for $1.4M; stock now at $53.85 near 52-week highs.

Wilson Marc, CFO of Crinetics Pharmaceuticals, sold 25,000 shares (a -18.4% reduction in holdings) at $55.00 on 2024-07-15, when the stock was near its 52-week high of $54.98. This occurred while the company faces significant headwinds: revenue declined -15.3% year-over-year, the latest quarter posted only $640.0K in revenue against a $-66.9M net loss, and the company remains unprofitable on a full-year basis. The stock has appreciated substantially over the preceding 90 days (+25.2%), yet this sale follows another sell by the same insider at CRNX on 2024-06-28, establishing a pattern of recent dispositions at elevated valuations. The timing—at or near the 52-week peak amid deteriorating fundamentals—merits monitoring of the company's clinical development and cash-burn trajectory.

Crinetics CFO Wilson Marc sells 32,129 shares at $43.61; company unprofitable with -15.3% annual revenue decline

Wilson Marc, the company's CFO, sold 32,129 shares (32.1K shares) at $43.61 on 2024-06-28, reducing his holdings by 22.4% from 143,221 to 111,092 shares. This divestment occurred while the company faces material headwinds: net income was negative at $-66,930,000.00 ($-66.9M) for the most recent full fiscal year, and annual revenue declined by 15.3% year-over-year. The stock currently trades at $45.54, modestly above the CFO's sale price, and remains 12.3% below its 52-week high. The combination of a significant insider reduction in equity stake, substantial net losses, and contracting revenue warrants investor attention to the company's operational trajectory and competitive position.